Wed, October 13, 2021
Tue, October 12, 2021
Mon, October 11, 2021

Judah Frommer Maintained (SRPT) at Hold with Increased Target to $100 on, Oct 12th, 2021

Judah Frommer of Credit Suisse, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Hold with Increased Target from $75 to $100 on, Oct 12th, 2021.

Judah has made no other calls on SRPT in the last 4 months.



There are 4 other peers that have a rating on SRPT. Out of the 4 peers that are also analyzing SRPT, 2 agree with Judah's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Matthew Harrison of "Morgan Stanley" Maintained at Hold with Decreased Target to $90 on, Monday, August 16th, 2021
  • Anupam Rama of "JP Morgan" Upgraded from Sell to Hold and Decreased Target to $87 on, Thursday, August 5th, 2021


These are the ratings of the 2 analyists that currently disagree with Judah


  • Whitney Ijem of "Guggenheim" Upgraded from Hold to Strong Buy on, Wednesday, September 15th, 2021
  • Tazeen Ahmad of "B of A Securities" Maintained at Strong Buy with Decreased Target to $122 on, Thursday, August 5th, 2021